Mazor Robotics (ADR) (NASDAQ:MZOR)

CAPS Rating: 3 out of 5

MZOR News and Commentary


How do you think MZOR will perform against the market?

Add Stock to CAPS Watchlist

All Players

80 Outperform
8 Underperform

All-Star Players

19 Outperform
2 Underperform

Wall Street

1 Outperform
0 Underperform

Top MZOR Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

TMFMattyA (99.81)
Submitted October 14, 2013

Below is part of a research report I recently did on Mazor Robotics (MZOR). Mazor is a very interesting company with compelling products and a vast market opportunity, but it also comes with significant risks. Buyer beware!Business DescriptionMazor… More

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!


MZOR Summary

Fools bullish on MZOR are also bullish on:

Fools bearish on MZOR are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about MZOR.


Member Avatar dfrizze (79.54) Submitted: 5/11/2017 12:46:44 PM : Outperform Start Price: $42.83 MZOR Score: -14.97

Robotic surgery for spinal issues. The next intuitive surgical


Member Avatar Capitalism (53.37) Submitted: 5/9/2017 10:45:28 AM : Outperform Start Price: $40.03 MZOR Score: -8.48

Baby ISRG?


Member Avatar lumbergh79 (< 20) Submitted: 5/28/2016 3:05:50 PM : Outperform Start Price: $16.44 MZOR Score: +110.34

The MDT investment and co marketing agreement is a huge deal to a company like this, but if MDT decides not to buy them out right, I have a hard time buying the long term value of them.

The problem (in my humble opinion) is the business model of companies like da Vinci and Mazor. High priced capital equipment with paltry disposable sales is a recipe for a long painful death of stockholder value. These companies operate in huge markets with high growth, but once the finite number of hospitals that (1) perform the specialty surgeries these platforms are made for and (2) can afford to spend $1mm on a product like this are fully penetrated, the company is left to survive on that paltry disposable revenue of $1500/case.

Take Stereotaxis as an example. They sell a system that allows cardiologist to maneuver catheters in a patients heart using magnets. The doctor is able to perform the procedure from the comfort and safety (no xray exposure) of the control room. Like da Vinci and Mazor, they sold their systems for $1mm+, hospital marketing departments fell all over themselves to advertise the latest cutting edge technology they were able to offer their communities, and the company made a small amount on their disposable (actually have a higher ASP on disposables than da Vinci and Mazor).

In 2007, Stereotaxis was trading at $161. By 2011, the price had dropped to $36. Today, they have sold all of the systems the market will bear and the stock trades for $1.20.

I really like the play for Medtronic. For $11.9mm (a rounding error for a company of that size), they get access to a platform in which they can develop a suite of products to drive the disposable ASP's to a level that will be a long term cash cow. For that inconsequential initial investment, their current sales force, and some RD resources to build a few new products to drive disposable ASP's, MDT could easily see an upside of $100-200mm in annual sales within 2-3 years. I suspect that Mazor doesnt have the financial, RD, or regulatory resources to bring products to market quickly, so MDT will likely be footing that bill...which means the VAST majority of the new revenue will belong to MDT...not Mazor.

Huge upside for Mazor to grow the top line in the near term, but could be a train wreck if the Medtronic co sell doesn't go exactly as hoped. MDT will easily recoup their initial investment in commissions in the next 12 months. If they don't like what they see, they will walk away with nothing lost.

MZOR is up 73% in the last 3 months. I'm sure it can/will continue to run up as the Medtronic co sell unfolds, but, if MDT walks away, that stock could look like Stereotaxis in short order.


Find the members with the highest scoring picks in MZOR.

Score Leader


mmhunter22 (< 20) Score: +223.25

The Score Leader is the player with the highest score across all their picks in MZOR.

Member Name Member
Call Time
Score Commentary
Dvinity 39.25 5/12/2016 Outperform 5Y $10.37 +257.67% +17.09% +240.58 0 Comment
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. vrpaul 55.60 2/2/2015 Outperform 5Y $10.79 +243.74% +21.32% +222.42 0 Comment
madcarl 59.67 5/9/2016 Outperform 5Y $11.16 +232.35% +18.07% +214.28 0 Comment
smith972 76.02 11/3/2014 Outperform 5Y $11.72 +216.47% +20.20% +196.27 1 Comment
martini74 < 20 2/17/2015 Outperform 5Y $11.94 +210.64% +15.91% +194.73 0 Comment
OldCountryBuffet < 20 1/5/2015 Outperform 5Y $11.99 +209.34% +18.88% +190.46 0 Comment
kaderoundy 88.65 5/26/2015 Outperform 5Y $12.95 +186.41% +14.27% +172.14 0 Comment
PK77 < 20 8/22/2014 Outperform 5Y $13.12 +182.70% +21.63% +161.07 0 Comment
MAKmeMONEY 27.24 6/2/2015 Outperform 5Y $13.65 +171.72% +14.49% +157.24 0 Comment
aguadaboca 30.00 6/3/2015 Outperform 3Y $13.90 +166.83% +14.26% +152.58 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Player Name Player
Call Time
Score End Date Commentary
TrackJimCramer 84.81 4/11/2017 Outperform 3W $28.63 0% 0% 0 0 Comment
TrackStandpoint 38.80 7/8/2016 Outperform 5Y $20.22 +64.97% +10.77% +54.20 4/20/2017 @ $33.36 0 Comment
TrackJimCramer 84.81 11/22/2013 Underperform 3W $17.28 +65.68% +28.59% -37.09 4/11/2017 @ $28.63 0 Comment

Featured Broker Partners